趙艷玲
趙艷玲：博士，研究員，博導(dǎo)，解放軍總醫(yī)院第五醫(yī)學(xué)中心藥學(xué)部主任，美國(guó)哈佛大學(xué)醫(yī)學(xué)院訪問學(xué)者，北京大學(xué)醫(yī)學(xué)部特聘教授。全軍科技拔尖人才，軍隊(duì)二等功、三等功獲得者，中華中醫(yī)藥學(xué)會(huì)中成藥分會(huì)主任委員。主持國(guó)家自然科學(xué)基金面上課題5項(xiàng)；國(guó)家自然科學(xué)基金重大項(xiàng)目課題1項(xiàng)；主持國(guó)家重點(diǎn)研發(fā)計(jì)劃、重大新藥創(chuàng)制專項(xiàng)、國(guó)家973計(jì)劃、國(guó)家863計(jì)劃等課題16項(xiàng)。獲國(guó)家科技進(jìn)步二等獎(jiǎng)2項(xiàng)；中華中醫(yī)藥學(xué)會(huì)科技進(jìn)步一等獎(jiǎng)2項(xiàng)；華夏醫(yī)學(xué)科技一等獎(jiǎng)1項(xiàng)；軍隊(duì)科技進(jìn)步二等獎(jiǎng)3項(xiàng)；北京市科技進(jìn)步二等獎(jiǎng)2項(xiàng)。先后在Applied Microbiology Biotechnology、中國(guó)科學(xué)、中國(guó)藥理學(xué)報(bào)等期刊發(fā)表論文300余篇。獲專利授權(quán)11項(xiàng)；任Mini Reviews in Medicinal Chemistry、《中草藥》、《中國(guó)藥房》等期刊編委，出版專著6部。
文章發(fā)表：
1.Qichao Hu, Yuan Chen, Xinyu Deng, Yubing Li, Xiao Ma, Jinhao Zeng*, Yanling Zhao*. Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. Biomedicine & Pharmacotherapy，159,2023,114252
2.Jiawei Wang, Jianxia Wen, Xiao Ma, Ju Yang, Zhao Zhang, Shuying Xie, Shizhang Wei, Manyi Jing, Haotian Li, Liwei Lang, Xuelin Zhou *, Yanling Zhao *. Validation of MAPK signalling pathway as a key role of paeoniflorin in the treatment of intrahepatic cholestasis of pregnancy based on network pharmacology and metabolomics. European Journal of Pharmacology, 935,2022,175331
3.Yuling Tong, Xu Zhao, Ruilin Wang, Ruisheng Li, Wenjun Zou*, YanlingZhao*. Therapeutic effect of berberine on chronic atrophic gastritis based on plasma and urine metabolisms. Eur J Pharmacol, 2021, 908:174335.
4.Wen J, Wu S, Ma X, Zhao Y. Zuojin Pill attenuates Helicobacter pylori-induced chronic atrophic gastritis in rats and improves gastric epithelial cells function in GES-1 cells. J Ethnopharmacol. 2022 Mar 1;285:114855.
5.Ying Wei, Ruilin Wang, Sichen Ren, Xia Liu, Manyi Jing, Ruisheng Li, Yuling Tong, Jianxia Wen, Tao Yang, Jian Wang*, YanlingZhao*. Zuojin Pill ameliorates inflammation in indomethacin-induced gastric injury via inhibition of MAPK pathway. J Ethnopharmacol, 2021, 275:114103.
承擔(dān)項(xiàng)目：
1.國(guó)家自然科學(xué)基金重大項(xiàng)目：基于臨床病證結(jié)合的吳茱萸類方減毒增效配伍評(píng)價(jià)及生物學(xué)基礎(chǔ)研究；項(xiàng)目批準(zhǔn)號(hào)：82192915；300萬元；2022年01月至 2026年 12月
2.國(guó)家重點(diǎn)研發(fā)計(jì)劃：總項(xiàng)目名稱：中藥配伍復(fù)方治療理論研究；總項(xiàng)目編號(hào)：2018YFC1704500；分課題名稱：基于有效組分解析技術(shù)的經(jīng)典名方左金丸治療理論研究分項(xiàng)目編號(hào)：2018YFC1704504，320萬，2018年12月至2021年12月。
3.國(guó)家自然科學(xué)基金（面上項(xiàng)目）：基于核受體FXR研究芍藥苷治療淤膽型肝炎的生物學(xué)機(jī)制；項(xiàng)目批準(zhǔn)號(hào)：81874365, 57萬元, 2019年1月-2022年12月
獲獎(jiǎng)情況：
1.基于性效整合模式的中藥治療難治性肝病應(yīng)用研究
北京市科學(xué)技術(shù)進(jìn)步二等獎(jiǎng) No:2019-J08-2-01-R01
2.中藥藥性認(rèn)知模式構(gòu)建與實(shí)踐
華夏醫(yī)學(xué)會(huì)科技進(jìn)步一等獎(jiǎng)No:201501051P1502